Encorafenib Production Cost Reports

The report provides a detailed analysis essential for establishing an Encorafenib production plant. It encompasses all critical aspects necessary for Encorafenib production, including the cost of Encorafenib production, Encorafenib plant cost, Encorafenib production costs, and the overall Encorafenib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Encorafenib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Encorafenib is used to treat advanced melanoma, a dangerous kind of skin cancer.  It is a member of the kinase inhibitor drug class. These medications function by preventing abnormal proteins from signaling to cancer cells to proliferate. It is also used in conjunction with another medication known as binimetinib. It is particularly effective for patients whose cancer has specific gene mutations known as BRAF V600E or V600K.

The market for Encorafenib is driven by its usage as an anticancer drug used for the treatment of melanoma, which significantly promotes its demand in the pharmaceutical and medical industries. The widespread occurrence of skin cancer is significantly increasing the demand for Encorafenib. The ability of Encorafenib to target specific gene mutations (BRAF), which are present in almost half the cases, amplifies its market appeal.

The drug’s utilization with binimetinib in a combination therapy further enhances its efficacy, thereby contributing to its market demand. Overall, industrial Encorafenib procurement is influenced by its application in the pharmaceutical and medical industries, rising cases of melanoma or skin cancer, ability to target specific gene mutations, increased efficacy in combination therapy, and regulatory approvals.

Raw Material for Encorafenib Production

According to the Encorafenib production plant project report, the key raw materials used in the production of Encorafenib include benzaldehyde- isopropylhydrazine hydrochloride.

Production Process of Encorafenib

The extensive Encorafenib production cost report consists of the following major industrial production process:

• Production from benzaldehyde and isopropylhydrazine hydrochloride: The production process of Encorafenib starts with the condensation reaction of benzaldehyde with isopropylhydrazine hydrochloride to form Schiff base. The Schiff base undergoes nucleophilic substitution reaction 2-(ethoxymethylene)malononitrile to give an intermediate. The intermediate is subjected to a cyclization reaction under acidic conditions to form pyrazole. The pyrazole undergoes nucleophilic addition reaction with methyl magnesium bromide to give ketone, which is iodinated and then subjected to aldol condensation with N,N-dimethylformamide (DMF) to give α,β-unsaturated ketone. The ketone is cyclized with guanidine hydrochloride to form pyrimidine. The amino group of the pyrimidine is further oxidized to alcohol. The alcohol undergoes chlorination reaction and subsequent substitution with amine to give another intermediate, which undergoes Suzuki coupling with borate ester to form the third intermediate. The Boc protective group is removed under acidic conditions to give the final intermediate. Finally, the intermediate undergoes sulfonylation and subsequent removal of the sulfonyl group to produce Encorafenib.

Encorafenib, commercially known as Braftovi, is a white crystalline powder having the molecular formula C22H27ClFN7O4S and a molecular weight of 540.0 g/mol. It has an estimated water solubility of 0.0112 mg/mL. It is slightly soluble in aqueous medium and insoluble at pH 3 or higher. It has a log P value of 4.16. The value of its dissociation constant, pKa, is 8.45. It is an oral RAF kinase inhibitor with anti-tumor effects used to treat melanoma or skin cancer.